Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 1/20 | 0.79 |
| ▸ | LTA4H | P09960 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.63 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.62 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylamine SCHEMBL27703437 | 0.96 | LSS (0.73) | LSSLTA4HKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL9851879 | 0.94 | LSS (0.70) | LSSLTA4HKDM4EALDH1A1SMN1; SMN2 | |
| Ethylamine SCHEMBL9873135 | 0.92 | LSS (0.69) | LSSLTA4HKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13886633 | 0.92 | LTA4H (0.83) | LSSLTA4HKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL9851898 | 0.92 | LSS (0.68) | LSSLTA4HKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL9491062 | 0.92 | LSS (0.68) | LSSLTA4HKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL9851880 | 0.92 | LSS (0.68) | LSSLTA4HKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL9851895 | 0.92 | LSS (0.68) | LSSLTA4HKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1405661 | 0.89 | LTA4H (0.85) | LSSLTA4HKDM4EALDH1A1HRH3 | |
| SCHEMBL9671156 | 0.89 | KDM4E (0.83) | LSSLTA4HKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115318256-A | Anion exchange-hydrophobic mixed mode chromatography resin | 生物辐射实验室股份有限公司 | 2022-11-11 | — | — | CN | claimed |
| CN-111818980-B | Anion exchange-hydrophobic mixed mode chromatography resins | 生物辐射实验室股份有限公司 | 2022-10-11 | — | — | CN | claimed |
| EP-1924553-A1 | BICYCLO[2.2.]HEPT-7-YLAMINE DERIVATIVES AND THEIR USES | Argenta Discovery Limited (GB) | 2008-05-28 | — | — | EP | claimed |
| CN-100383138-C | N-monoacetyl o-phenylenediamines, their fused heterocyclic derivatives and their use as medicaments | HOFFMANN LA ROCHE (CH) | 2008-04-23 | — | — | CN | claimed |
| WO-2007017670-A1 | BICYCLO[2.2.]HEPT-7-YLAMINE DERIVATIVES AND THEIR USES | ARGENTA DISCOVERY LTD. (GB) | 2007-02-15 | — | — | WO | claimed |
| CN-1747948-A | Novel n-monoacylated o-phenylenediamines, their condensed heterocyclic derivatives and their use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2006-03-15 | — | — | CN | claimed |
| US-12583818-B2 | Compound, preparation method thereof, and use thereof | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2026-03-24 | — | — | US | disclosed |
| US-12343702-B2 | Anionic exchange-hydrophobic mixed mode chromatography resin | BIO-RAD LABORATORIES, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250196100-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESIN | BIO-RAD LABORATORIES, INC. | 2025-06-19 | — | — | US | disclosed |
| CN-114981241-B | Novel compounds, process for their preparation and their use | 大邱庆北尖端医疗产业振兴财团 | 2024-11-19 | — | — | CN | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| CN-1304380-C | Benzo[a]henazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | XENOVA LTD (GB) | 2007-03-14 | — | — | CN | disclosed |
| US-7183409-B2 | Basic mono- and bisazo compounds | CLARIANT FINANCE (BVI) LIMITED (VG) | 2007-02-27 | — | — | US | disclosed |
| US-7183409-B2 | Basic mono- and bisazo compounds | CLARIANT FINANCE (BVI) LIMITED (VG) | 2007-02-27 | — | — | US | disclosed |
| WO-2007017670-A1 | BICYCLO[2.2.]HEPT-7-YLAMINE DERIVATIVES AND THEIR USES | ARGENTA DISCOVERY LTD. (GB) | 2007-02-15 | — | — | WO | disclosed |
| CN-1747948-A | Novel n-monoacylated o-phenylenediamines, their condensed heterocyclic derivatives and their use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2006-03-15 | — | — | CN | disclosed |
| CN-1433406-A | Benzo [ a ] phenazine-11-amide derivatives and their use as combined topoisomerase I and II inhibitors | XENOVA LTD (GB) | 2003-07-30 | — | — | CN | disclosed |
| US-5021429-A | Histamine h2-antagonists; antisecretory-antiallergen agent; skin disorders and peptic ulcers | ALLEN & HANSBURYS LIMITED (GB) | 1991-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583818-B2 | Compound, preparation method thereof, and use thereof | TYRO3, TH, SRMS | LSS 744/4885LTA4H 1459/4885KDM4E 2818/4885 |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | TYR, TYRO3, TH | LSS 1325/4885LTA4H 930/4885KDM4E 619/4885 |
| US-20250196100-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESIN | SLC7A1, ABCG2, MSR1 | LSS 4236/4885LTA4H 1282/4885KDM4E 3608/4885 |
| US-12343702-B2 | Anionic exchange-hydrophobic mixed mode chromatography resin | FCGRT, PBRM1, BCR | LSS 4841/4885LTA4H 3846/4885KDM4E 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.